Mark Sentenac

Mark Sentenac helps companies address their most complex litigation, discovery, and technology-related risks. He represents leading life sciences, technology, social media, automotive, and industrial companies in high-stakes mass torts and is particularly recognized for leading sophisticated discovery and data-management efforts in large-scale litigation. His practical, business-focused approach helps clients reduce risk, create efficiencies, and achieve favorable outcomes.

Mark defends companies in all phases of mass tort, product liability, and cutting-edge “tech tort” litigation in the most difficult jurisdictions. Mark has extensive experience helping companies navigate increasingly risky and complex discovery issues in mass tort litigation. This includes serving as lead discovery counsel to clients in the In re Social Media Adolescent Addiction/Personal Injury Litigation and the Zantac (Ranitidine) Products Liability Litigation.  

Mark has also been at the forefront of advising companies on the potential product liability risks of implementing AI. He is a member of the firm’s AI/ML Tactical Operations team and leads the Product Liability & Mass Tort group’s technology and innovation initiatives seeking to achieve better results and drive efficiencies for clients and the firm through implementation of new technologies.

Mark is also widely published on cutting edge litigation issues of significance to the life sciences industry, including Mitigating Risks of Developing Drugs and Devices with AI, Law360 (Jul. 2023)—named by Law360 as a Top Guest Article for 2023—Medical Device Makers Must Review Approach After California Case, Bloomberg Law (Jul. 2024), FDA’s Essure Order Affirms Role of Learned Intermediary, Law360 (Apr 2018), and Will The Learned Intermediary Doctrine Survive A New Paradigm?, Law360 (Jan 2017).